Prophylactic transarterial chemoembolization after R0 resection is beneficial to improve the prognosis in hepatocellular carcinoma patients with microvascular invasion
Abstract Objective Microvascular invasion (MVI) is a risk factor for disease recurrence and worse survival in hepatocellular carcinoma (HCC) patients after radical resection. This study aimed to investigate the efficacy of prophylactic transarterial chemoembolization (TACE) after R0 resection in HCC...
Saved in:
| Main Authors: | Wenjie Sun, Yafang Li, Haozhe Fu, Jiangze Li, Jinbao Li |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-06-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-02722-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Transarterial chemoembolization combined with apatinib in the treatment of advanced hepatocellular carcinoma: a prospective, multi-center, real-world study (Ahend-HAP02)
by: Hang Yuan, et al.
Published: (2025-07-01) -
Transarterial Chemoembolization With or Without Systemic Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Comparative Study
by: Chengxiang Guo, et al.
Published: (2025-02-01) -
Efficacy and safety of lenvatinib plus transarterial chemoembolization with or without programmed death-1 inhibitors in the treatment of intermediate or advanced hepatocellular carcinoma: a systematic review and meta-analysis
by: Yongfa Lei, et al.
Published: (2025-07-01) -
Identification of transarterial chemoembolization candidates in advanced hepatocellular carcinoma patients classified solely by performance status 1: a multicenter retrospective study
by: Jing Li, et al.
Published: (2025-05-01) -
Transarterial chemoembolization plus apatinib for unresectable hepatocellular carcinoma: a multicenter, randomized, open-label, phase III trial
by: Xue-Feng Kan, et al.
Published: (2025-05-01)